Mannkind Corporation: all 66 studies
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07679893Phase 2
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesRecruitingNCT07224321Phase 2
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersRecruitingNCT06532942Phase 1
- Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy VolunteersCompletedNCT06167707Phase 1Results posted
- Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesCompletedNCT05243628Phase 4Results posted
- Afrezza® Dosing Optimization StudyCompletedNCT04849845Phase 4Results posted
- Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot StudyCompletedNCT04593823Phase 2Results posted
- Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart FailureCompletedNCT03458325Phase 3Results posted
- Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsCompletedNCT02527265Phase 2Results posted
- Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart FailureCompletedNCT02329834Phase 2/3Results posted
- Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusCompletedNCT01451398Phase 3Results posted
- Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment PeriodCompletedNCT01445951Phase 3Results posted
- Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 InhalerTerminatedNCT01196104Phase 3Results posted
- An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' TrialCompletedNCT00754624Phase 2Results posted
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate IntakeTerminatedNCT00747006Phase 2Results posted
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-WeeksTerminatedNCT00700622Phase 3Results posted
- A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin LisproCompletedNCT00662857Phase 2Results posted
- Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseTerminatedNCT00642616Phase 3Results posted
- A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 DiabetesCompletedNCT00570687Phase 2Results posted
- Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 DiabetesCompletedNCT00332488Phase 3Results posted
- Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upCompletedNCT00309244Phase 3Results posted
- Safety of Inhaled Insulin With Type 1 and Type 2 DiabetesCompletedNCT00308737Phase 3Results posted
- Efficacy & Safety of Inhaled Insulin in Type 1 DiabetesCompletedNCT00308308Phase 3Results posted
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT07344558Phase 1
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionTerminatedNCT06418711Phase 3
- INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesCompletedNCT05904743Phase 4
- Afrezza® INHALE-1 Study in PediatricsCompletedNCT04974528Phase 3
- An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin TolerabilityCompletedNCT04161482Phase 1
- Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal VolunteersCompletedNCT03464864Phase 1
- Product Design Clinical Performance Study of sc2Wear Furosemide Combination ProductCompletedNCT02804282Phase 3
- Pilot Study for First Clinical Use of sc2Wear Furosemide Combination ProductCompletedNCT02804035Phase 2
- Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone AdministrationCompletedNCT02561442Phase 2/3
- PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)CompletedNCT02485327Phase 1
- Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes MellitusCompletedNCT02470637Phase 1
- Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral AdministrationCompletedNCT02350725Phase 1/2
- Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different SuppliersCompletedNCT01982604Phase 1
- Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 CartridgeCompletedNCT01902121Phase 1
- Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation PowderNo longer availableNCT01798914
- Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 DiabetesCompletedNCT01544881Phase 1
- Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C InhalerCompletedNCT01490762Phase 1
- Pharmacokinetic Study in Healthy VolunteersCompletedNCT01365117Phase 1
- Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166TerminatedNCT01201928
- Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With MelanomaTerminatedNCT01026051Phase 2
- A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01021891Phase 1
- Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 DiabetesCompletedNCT00934414Phase 2
- A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)CompletedNCT00757367Phase 1
- A 2-Month Safety Follow-Up TrialCompletedNCT00741429
- A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.CompletedNCT00721344Phase 1
- Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.CompletedNCT00688090Phase 1
- A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy VolunteersCompletedNCT00674050Phase 1
- A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmaticsCompletedNCT00673621Phase 1
- Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal ChallengeCompletedNCT00642681
- A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedNCT00642538Phase 1
- Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney FunctionCompletedNCT00626249Phase 1
- Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes MellitusCompletedNCT00539890Phase 3
- A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin GlargineCompletedNCT00539396Phase 2
- Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human InsulinCompletedNCT00511979Phase 1
- 18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 DiabetesCompletedNCT00511732Phase 2
- Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 DiabetesCompletedNCT00511719Phase 2
- Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 DiabetesCompletedNCT00511602Phase 2
- A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesCompletedNCT00475371Phase 1
- Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.CompletedNCT00423254Phase 1
- To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.CompletedNCT00419302Phase 2
- Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and AsthmaTerminatedNCT00332826Phase 3
- Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00033228Phase 1/2
- Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00023647Phase 1